CIK 0001626199
ALPN ALPINE IMMUNE SCIENCES, INC.
Insider trading from SEC Form 4. Last filing May 20, 2024.
In brief
ALPINE IMMUNE SCIENCES, INC. (ALPN) has 49 SEC Form 4 filings on file from 14 insiders, the latest filed on May 20, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
15 open-market trades have been scored at ALPN. The newest: James N Topper (director) sold $1,227 of stock on Apr 25, 2024, filed Apr 29, 2024, scored 15 (weak). The largest of the 15 shown: Orbimed Advisors LLC (director) sold $29M on Dec 27, 2023, scored 65 (notable). 4 insiders sold within 14 days of each other around Dec 27, 2023.
9 Form 144 notices of planned sales are on file, the latest filed Jan 26, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Signals
Open-market buys and sells at ALPINE IMMUNE SCIENCES, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | James N Topper director sell | $1,227 19 shares | -0% | - | |
| 25Weak | James Paul Rickey See Remarks sell | $2.8M 118,000 shares | -50000% | - | |
| 65Notable | Orbimed Advisors LLC director sell | $29M 1,546,347 shares | -42% | - | |
| 65Notable | Peter A. Thompson director sell | $29M 1,546,347 shares | -42% | - | |
| 25Weak | Mitchell Gold Executive Chairman and CEO sell | $20k 1,016 shares | -100% | - | |
| 50Moderate | Mitchell Gold Executive Chairman and CEO sell | $1.9M 91,884 shares | -243% | - | |
| 32Weak | Mitchell Gold Executive Chairman and CEO sell | $48k 2,402 shares | -100% | - | |
| 29Weak | James Paul Rickey See Remarks sell | $292k 15,213 shares | -100% | - | |
| 40Moderate | James Paul Rickey See Remarks sell | $1.1M 58,787 shares | -507% | - | |
| 43Moderate | Mitchell Gold Executive Chairman and CEO sell | $2.0M 118,000 shares | -108% | - | |
| 33Weak | James Paul Rickey See Remarks sell | $1.1M 70,811 shares | -111% | - | |
| 8Weak | James Paul Rickey See Remarks sell | $11k 700 shares | -100% | - | |
| 54Moderate | Xiangmin Cui director, owner buy | $4.7M 375,000 shares | +28% | - | |
| 46Moderate | Decheng Capital Global Healthcare Fund (Master), LP owner buy | $4.7M 375,000 shares | +28% | - | |
| 14Weak | James Paul Rickey See Remarks sell | $289k 18,003 shares | -100% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 26, 2024 | JAMES PAUL RICKEY Officer | 44,000 0.08% of outstanding | $957k | Jan 26, 2024 | $2.9M |
| Jan 25, 2024 | JAMES PAUL RICKEY Officer | 74,000 0.13% of outstanding | $1.4M | Jan 25, 2024 | $2.9M |
| Dec 27, 2023 | OrbiMed Genesis Master Fund, L.P. Shareholder | 161,216 0.28% of outstanding | $3.3M | Dec 27, 2023 | none |
| Dec 27, 2023 | OrbiMed Private Investments VI, LP Shareholder | 1,385,131 2.38% of outstanding | $28M | Dec 27, 2023 | none |
| Dec 19, 2023 | Mitchell H. Gold Officer | 120,000 0.21% of outstanding | $2.4M | Dec 19, 2023 | $2.0M |
| Dec 15, 2023 | JAMES PAUL RICKEY Officer | 62,400 0.11% of outstanding | $1.2M | Dec 15, 2023 | $1.7M |
| Dec 14, 2023 | JAMES PAUL RICKEY Officer | 11,600 0.02% of outstanding | $218k | Dec 14, 2023 | $1.4M |
| Dec 8, 2023 | Mitchell H. Gold Officer | 118,000 0.20% of outstanding | $2.0M | Dec 8, 2023 | none |
| Nov 6, 2023 | JAMES PAUL RICKEY Officer | 89,514 0.18% of outstanding | $1.4M | Nov 6, 2023 | none |
Transactions
The newest 50 of 244 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2024 | Ulrich Martin Fuhs Chief Accounting Officer | DDisposition to issuer Common Stock | -22,820 | - | - | 7,300 | May 20, 2024 |
| May 20, 2024 | Jorn Drappa director | DDisposition to issuer Stock Option (Right to buy)derivative | -20,000 | - | - | 0 | May 20, 2024 |
| May 18, 2024 | Peter A. Thompson director | UTender of shares Common Stockindirect: See Footnotes | -2,416,181 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Remy Durand Chief Business Officer | DDisposition to issuer Common Stock | -102,192 | - | - | 31,200 | May 20, 2024 |
| May 18, 2024 | James N Topper director | UTender of shares Common Stockindirect: By Frazier Life Sciences VIII, L.P. | -2,829,347 | - | - | 0 | May 20, 2024 |
| May 18, 2024 | Mitchell Gold Executive Chairman and CEO | UTender of shares Common Stockindirect: Alpine ImmunoSciences, L.P. | -2,627,157 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | James Paul Rickey See Remarks | DDisposition to issuer Common Stock | -26,761 | - | - | 31,200 | May 20, 2024 |
| May 20, 2024 | Stanford L Peng See Remarks | DDisposition to issuer Common Stock | -296,163 | - | - | 48,000 | May 20, 2024 |
| May 18, 2024 | Xiangmin Cui director, owner | UTender of shares Common Stockindirect: See Footnote | -6,582,380 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Natasha Hernday director | DDisposition to issuer Stock Option (Right to buy)derivative | -15,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Robert E Conway director | DDisposition to issuer Common Stockindirect: By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust | -50,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Christopher Peetz director | DDisposition to issuer Common Stockindirect: Christopher Peetz & Christine Peetz TR UA 02/15/2017 The Peetz Living Trust | -1,900 | - | - | 0 | May 20, 2024 |
| May 18, 2024 | Orbimed Advisors LLC director | UTender of shares Common Stockindirect: See footnotes | -2,416,181 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Remy Durand Chief Business Officer | DDisposition to issuer Common Stock | -31,200 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | James Paul Rickey See Remarks | DDisposition to issuer Common Stock | -31,200 | - | - | 0 | May 20, 2024 |
| May 18, 2024 | Peter A. Thompson director | UTender of shares Common Stockindirect: See Footnotes | -264,315 | - | - | 0 | May 20, 2024 |
| May 18, 2024 | Orbimed Advisors LLC director | UTender of shares Common Stockindirect: See footnotes | -264,315 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Ulrich Martin Fuhs Chief Accounting Officer | DDisposition to issuer Common Stock | -7,300 | - | - | 0 | May 20, 2024 |
| May 18, 2024 | Xiangmin Cui director, owner | UTender of shares Common Stockindirect: See Footnote | -1,735,544 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Natasha Hernday director | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Robert E Conway director | DDisposition to issuer Stock Option (Right to buy)derivative | -2,868 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Stanford L Peng See Remarks | DDisposition to issuer Common Stock | -48,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Christopher Peetz director | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Jorn Drappa director | DDisposition to issuer Stock Option (Right to buy)derivative | -10,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Mitchell Gold Executive Chairman and CEO | DDisposition to issuer Common Stock | -13,245 | - | - | 96,000 | May 20, 2024 |
| May 20, 2024 | James N Topper director | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Peter A. Thompson director | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Jorn Drappa director | DDisposition to issuer Stock Option (Right to buy)derivative | -17,500 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | James Paul Rickey See Remarks | DDisposition to issuer Stock Option (Right to buy)derivative | -836 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | James N Topper director | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Remy Durand Chief Business Officer | DDisposition to issuer Stock Option (Right to buy)derivative | -2,635 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Xiangmin Cui director, owner | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Natasha Hernday director | DDisposition to issuer Stock Option (Right to buy)derivative | -10,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Ulrich Martin Fuhs Chief Accounting Officer | DDisposition to issuer Stock Option (Right to buy)derivative | -52,180 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Christopher Peetz director | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Stanford L Peng See Remarks | DDisposition to issuer Stock Option (Right to buy)derivative | -42,407 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Robert E Conway director | DDisposition to issuer Stock Option (Right to buy)derivative | -3,075 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Mitchell Gold Executive Chairman and CEO | DDisposition to issuer Common Stock | -96,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | James N Topper director | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Mitchell Gold Executive Chairman and CEO | DDisposition to issuer Stock Option (Right to buy)derivative | -70,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Remy Durand Chief Business Officer | DDisposition to issuer Stock Option (Right to buy)derivative | -26,922 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Peter A. Thompson director | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Natasha Hernday director | DDisposition to issuer Stock Option (Right to buy)derivative | -10,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | James Paul Rickey See Remarks | DDisposition to issuer Stock Option (Right to buy)derivative | -137 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Robert E Conway director | DDisposition to issuer Stock Option (Right to buy)derivative | -1,912 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Xiangmin Cui director, owner | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Christopher Peetz director | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Ulrich Martin Fuhs Chief Accounting Officer | DDisposition to issuer Stock Option (Right to buy)derivative | -28,700 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Stanford L Peng See Remarks | DDisposition to issuer Stock Option (Right to buy)derivative | -236,623 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | Mitchell Gold Executive Chairman and CEO | DDisposition to issuer Stock Option (Right to buy)derivative | -247,951 | - | - | 0 | May 20, 2024 |
50 of 244 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Robert E Conwaydirector, other
- Xiangmin Cuiowner, director
- Remy DurandChief Business Officer
- Decheng Capital Global Healthcare Fund (Master), LPowner
- Jorn Drappaofficer, director
- Ulrich Martin FuhsChief Accounting Officer
- Mitchell GoldExecutive Chairman and CEO
- Natasha Herndaydirector
- Orbimed Advisors LLCdirector, owner
- Stanford L PengSee Remarks
- Christopher Peetzceo, officer, director, president
- James Paul RickeySee Remarks
- Peter A. Thompsondirector, owner
- James N Topperdirector, owner
Questions about ALPN
Answered from the filings on this page, as of the latest one.
Are insiders buying ALPN?
No. In the last 90 days no insider at ALPINE IMMUNE SCIENCES, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ALPN on the open market?
James N Topper (director) sold $1,227 of ALPN on Apr 25, 2024 and filed the Form 4 on Apr 29, 2024. InsiderTell scored 15 (weak).
How many insiders file Form 4 at ALPINE IMMUNE SCIENCES, INC.?
14 people have filed a Form 4 at ALPINE IMMUNE SCIENCES, INC., among them Robert E Conway (director), Xiangmin Cui (10% owner and director), Remy Durand (Chief Business Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.